1. Resnick K.E., Hampel H., Fishel R. et al. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 2009; 114(1): 128 - 34.

2. Van den Bosch T., Coosemans A., Morina M. et al. Screening for uterine tumours. Best Pract Res Clin Obstet Gynaecol 2012; 26(2): 257 - 66.

3. Dinkelspiel H.E., Wright J.D., Lewin S.N. et al. Contemporary clinical management of endometrial cancer. Obstet Gynecol Int 2013; 2013.

4. Бохман Я.В. Руководство по онкогинекологии. М.: Медицина, 1989. 325 с.

5. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2018 г. (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2019. 250 с.

6. Kurman R.J., Carcangiu M.L., Harrington C.S., Young R.H. et al. WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press, 2014. World Health Organization Classification of Tumors. 4^th edn.

7. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet 2009; 105(2): 103 - 4.

8. Amanta F., Mirzab M., Creutzbergc C. FIGO cancer report 2012. Cancer of the corpus uteri. Int J Gynecol Obstet 2012; 119(S 2): S110 - 7.

9. Cade T.J., Quinn M.A., McNally O.M. et al. Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment? Int J Gynecol Cancer 2010; 20(7): 1166 - 9.

10. Brierley J., Gospodarowicz M.K., Wittekind Ch. TNM classification of malignant tumours. Oxford, UK; Hoboken, NJ: John Wiley & Sons, Inc., 2017.

11. Ortashi O., Jain S., Emannuel O. et al. Evaluation of the sensitivity, specificity, positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer. A prospective study of 100 cases at the Dorset Cancer Centre. Eur J Obstet Gynecol Reprod Biol 2008; 137(2): 232 - 5.

12. Koskas M., Bendifallah S., Luton D. et al. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril 2012; 98(5): 1229 - 35.

13. Shah J.P., Bryant C.S., Kumar S. et al. Lymphadenectomy and Ovarian Preservation in Low-Grade Endometrial Stromal Sarcoma. Obstet Gynecol 2008; 112: 1102 - 8.

14. Kitajima K., Suzuki K., Senda M. et al. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone? Ann Nucl Med 2011; 25(7): 511 - 9.

15. Antonsen S.L., Jensen L.N., Loft A. et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer-a multicenter prospective comparative study. Gynecol Oncol 2013; 128(2): 300 - 8.

16. Kwon J.S., Scott J.L., Gilks C.B. et al. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011; 29(16): 2247 - 52.

17. Crispens M.A. Endometrial and ovarian cancer in lynch syndrome. Clin Colon Rectal Surg 2012; 25(2): 97 - 102.

18. Walker J.L., Piedmonte M.R., Spirtos N.M. et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012; 30(7): 695 - 700.

19. Wang H.L., Ren Y.F., Yang J. et al. Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. Asian Pac J Cancer Prev 2013; 14(4): 2515 - 9.

20. Krill L.S., Bristow R.E. Robotic surgery: gynecologic oncology. Cancer J 2013; 19(2): 167 - 76.

21. Wright J.D., Buck A.M., Shah M. et al. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009; 27(8): 1214 - 9.

22. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005; 106(2): 413 - 25.

23. Mourits M.J., Bijen C.B., Arts H.J. et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 2010; 11(8): 763 - 71.

24. Niazi T.M., Souhami L., Portelance L. et al. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I - II endometrial carcinoma. Int J Radiat Oncol Biol Phys 2005; 63(4): 1108 - 13.

25. Fan Z., Li H., Hu R. et al. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis. Int J Gynecol Cancer 2018; 28(2): 385 - 93.

26. Wei J., Zhang W., Feng L., Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review. Medicine (Baltimore) 2017; 96(37): e8034.

27. Colombo N., Creutzberg C., Amant F. et al. ESMO-ESGO-ESTRO Consensus conference on endometrial cancer. Diagnosis, treatment and follow-up. Int J Gynecol Cancer 2016; 26(1): 2 - 30.

28. Kitchener H., Swart A.M., Qian Q. et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009; 373 (9658): 125 - 36.

29. Yamagami W., Susumu T. Makabe et al. Yamagami W. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 2018; 29(2): e21.

30. Minig L., Franchi D., Boveri S. et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011; 22: 643 - 9.

31. Kim M.K., Ju. Seong Seok, Kim You Shin et al. Combined medroxyprogesterone acetate/levonorgestreleintrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol 2013; 209: 358.e1-4.

32. Park J.Y., Kim D.Y., Kim J.H. et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG2002). Eur J Cancer 2013; 49: 868 - 74.

33. Lee T.S., Lee J.Y., Kim J.W. et al. Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. Gynecol Oncol 2013; 131(2): 289 - 93.

34. Benedetti Panici P., Basile S., Maneschi F. et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008; 100(23): 1707 - 16.

35. Fishman D.A., Roberts K.B., Chambers J.T. et al. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 1996; 61(2): 189 - 96.

36. Coon D., Beriwal S., Heron D.E. et al. High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. Int J Radiat Oncol Biol Phys 2008; 71(3): 779 - 83.

37. Boente M.P., Yordan E.L. Jr, McIntosh D.G. et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 1993; 51(3): 316 - 22.

38. Sartori E., Gadducci A., Landoni F. et al. Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy.

39. Garg G., Jah J.P., Liu J.R. et al. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma. A population-based study. Int J Gynecol Cancer 2010; 20: 1201 - 6.

40. Bouchard M., Nadeau S., Gingras L. et al. Clinical outcome of adjuvant treatment of endometrial cancer using aperture-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008; 71: 1343 - 50.

41. Beriwal S., Jain S.K., Heron D.E. et al. Clinical outcome with adjuavant treatment of endometrial carcinoma using intensity-modulated radiation therapy. Gynecol Oncol 2006; 102: 195 - 9.

42. Roper B., Astner S.T., Heydemann-Obradovic A. et al. Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol 2007; 107: 541 - 8.

43. Nout R.A., Putter H., Jurgenliemk-Schulz I.M. et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27: 3547 - 56.

44. Le T., Menard C., Samant R, et al. Longitudinal assessments of quality of life in endometrial cancer patients: effect of surgical approach and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75: 795 - 802.

45. Klopp A., Smith B.D., Alektiar K. et al. The role of postoperative radiation therapy for endometrial cancer: executive summary of an american society for radiation oncology evidence-based guideline. Pract Radiat Oncol 2014; 4: 137 - 44.

46. Elshaikh M.A., Al-Wahab Z., Mahdi H. et al. Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol 2015; 136: 235 - 9.

47. Secord A.A., Havrilesky L.J., O'Malley D.M. et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol 2009; 114(3): 442 - 7.

48. Berton-Rigaud D., Devouassoux-Shisheboran M., Ledermann J.A. et al. Gynecologic Cancer Inter Group (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer 2014; 24 (9 Suppl 3): S55 - 60.

49. Fader A.N., Roque D.M., Siegel E. et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol 2018; 36(20): 2044 - 51.

50. Cella D., Huang H., Homesley H.D. et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. Gynecol Oncol 2010; 119: 538 - 42.

51. Fleming G.F., Brunetto V.L., Cella D. et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159 - 66.

52. Miller D., Filiaci V., Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study [abstract]. Gynecologic Oncology 2012; 125: 771.

53. Fiorica J.V., Brunetto V.L., Hanjani P. et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 10 - 4.

54. Altman A.D., Thompson J., Nelson G. et al. Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study. J Obstet Gynaecol Can 2012; 34: 664 - 72.

55. Judson I., Radford J.A., Harris M. et al. Randomized phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001; 37(7): 870 - 7.

56. Hensley M.L., Blessing J.A., Mannel R., Rose P.G. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109(3): 329 - 34.

57. Barker L.C., Brand I.R., Crawford S.M. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. Curr Med Res Opin 2009; 25: 1105 - 9.

58. Whitney C.W., Brunetto V.L., Zaino R.J. et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92: 4 - 9.

59. Herzog T.J. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? Gynecol Oncol 2004; 92: 1 - 3.

60. Singh M., Zaino R.J., Filiaci V.J., Leslie K.K. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007; 106: 325 - 33.

61. Wadler S., Levy D.E., Lincoln S.T. et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol 2003; 21: 2110 - 4.

62. Traina T.A., Sabbatini P., Aghajanian C., Dupont J. Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature. Gynecol Oncol 2004; 95: 235 - 41.

63. Sutton G., Blessing J.A., Malfetano J.H. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62(2): 226 - 9.

64. Zalupski M., Metch B., Balcerzak S. et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83(13): 926 - 32.

65. Garcia-Del-Muro X., Lopez-Pousa A., Maurel J. et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29 (18): 2528 - 33.

66. Dileo P., Morgan J., Zahrieh D. et al. Gemcitabine and vinorel-bine combination chemotherapy for patients with advanced soft tissue sarcomas. Cancer 2007; 109(9): 1863 - 9.

67. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN ) for Uterine Neoplasms V1.2018. Available at: http://www.nccn.org/ professionals/physician_gls/pdf/uterine.pdf. Accessed March 21, 2018.

68. Look K.Y., Sandler A., Blessing J.A. et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 2004; 92(2): 644 - 7.

69. Decruze S.B., Green J.A. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17: 964 - 78.

70. Miller D.S., Blessing J.A., Lentz S.S., Waggoner S.E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2002; 87: 247 - 51.

71. Muggia F.M., Blessing J.A., Sorosky J., Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002; 20: 2360 - 4.

72. Aghajanian C., Sill M.W., Darcy K.M. et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2011; 29: 2259 - 65.

73. Mendivil A., Schuler K.M., Gehrig P.A. Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009; 16: 46 - 52.

74. Fader A.N., Nagel C., Axtell A.E. et al. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. Gynecol Oncol 2009; 112: 558 - 62.

75. Mouridsen H.T., Bastholt L., Somers R. et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987; 23(10): 1477 - 83.

76. Sutton G.P., Blessing J.A., Barrett R.J. et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166(2): 556 - 9.

77. Amant F., Coosemans A., Debiec-Rychter M. et al. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10(12): 1188 - 98.

78. van der Graaf W.T., Blay J.Y., Chawla S.P. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379(9829): 1879 - 86.

79. Demetri G.D., Chawla S.P., von Mehren M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthra-cyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27(25): 4188 - 96.

80. Muggia F., Blessing J.A., Method M. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92(2): 639 - 40.

81. Garcia A.A., Blessing J.A., Nolte S., Mannel R.S. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol 2008; 111(1): 22 - 6.

82. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6): 649 - 655

83. Karnofsky DA, Burchenal JH: The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. edn. Edited by MacLeod C. New York: Columbia University Press; 1949: 191 - 205

84. Colombo N. et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up//Annals of oncology. - 2013. - Т. 24. - N. suppl_6. - С. vi33 - vi38.

85. Chen Y. et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 and their combination for endometrial cancer diagnosis: a meta-analysis//Eur Rev Med Pharmacol Sci. - 2016. - Т. 20. - N. 10. - С. 1974 - 1985.

86. Epstein E. et al. Ultrasound characteristics of endometrial cancer as defined by International Endometrial Tumor Analysis (IETA) consensus nomenclature: prospective multicenter study//Ultrasound in Obstetrics & Gynecology. - 2018. - Т. 51. - N. 6. - С. 818 - 828.

87. Breitkopf D. M. et al. Direct aspiration endometrial biopsy via flexible hysteroscopy//Journal of minimally invasive gynecology. - 2012. - Т. 19. - N. 4. - С. 490 - 493.

88. Kinkel K. et al. Radiologic staging in patients with endometrial cancer: a meta-analysis//Radiology. - 1999. - Т. 212. - N. 3. - С. 711 - 718.

92. Fares R., Kehoe S., Shams N. Preoperative Prediction of Lymph Nodal Metastases in Endometrial Carcinoma: Is it Possible?//International Journal of Gynecologic Cancer. - 2018. - Т. 28. - N. 2. - С. 394 - 400.

93. Chang, M.-C., Chen, J.-H., Liang, J.-A., Yang, K.-T., Cheng, K.-Y., & Kao, C.-H. (2012). 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: A systematic review and meta-analysis. European Journal of Radiology, 81(11), 3511 - 3517. doi:10.1016/j.ejrad.2012.01.024

94. Singh S., Resnick K. E. Lynch Syndrome and Endometrial Cancer//Southern medical journal. - 2017. - Т. 110. - N. 4. - С. 265 - 269

95. Gu H. et al. Survival impact of ovarian preservation on women with early-stage endometrial cancer: a systematic review and meta-analysis//International Journal of Gynecologic Cancer. - 2017. - Т. 27. - N. 1. - С. 77 - 84.

96. Lee B. et al. Influence of positive peritoneal cytology on prognostic factors and survival in early-stage endometrial cancer: a systematic review and meta-analysis//Japanese journal of clinical oncology. - 2016. - Т. 46. - N. 8. - С. 711 - 717

97. Xiu X. X. et al. Endometrial stromal sarcoma in combination with mixed type endometrial carcinomas: A case report and literature review//Medicine. - 2017. - Т. 96. - N. 49.

98. Van WIJK, F.H., HUIKESHOVEN, F. J., ABDULKADIR, L., EWING, P. C., & BURGER, C. W. (2006). Stage III and IV endometrial cancer: a 20-year review of patients. International Journal of Gynecological Cancer, 16(4), 1648 - 1655.

99. Huang C. Y. et al. Impact of lymphadenectomy in uterine endometrioid carcinoma//European Journal of Surgical Oncology (EJSO). - 2013. - Т. 39. - N. 4. - С. 350 - 357

100. Comert G. K. et al. Therapy modalities, prognostic factors, and outcome of the primary cervical carcinosarcoma: Meta-analysis of extremely rare tumor of cervix//International Journal of Gynecologic Cancer. - 2017. - Т. 27. - N. 9. - С. 1957 - 1969.

101. Roberts M. E., Aynardi J. T., Chu C. S. Uterine leiomyosarcoma: A review of the literature and update on management options//Gynecologic oncology. - 2018. - Т. 151. - N. 3. - С. 562 - 572.

102. Si M. et al. Role of lymphadenectomy for uterine sarcoma: a meta-analysis//International Journal of Gynecologic Cancer. - 2017. - Т. 27. - N. 1. - С. 109 - 116.

103. Jenabi E., Poorolajal J. The effect of body mass index on endometrial cancer: a meta-analysis//Public health. - 2015. - Т. 129. - N. 7. - С. 872 - 880.

104. Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Miller, D. S. (2019). Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. New England Journal of Medicine, 380(24), 2317 - 2326.

105. Kong A. et al. Adjuvant radiotherapy for stage I endometrial cancer//Cochrane Database of Systematic Reviews. - 2012. - N. 3.

106. Eftekhar Z et al. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients./ Int J Gynecol Cancer. 2009 Feb; 19(2): 249 - 52. doi: 10.1111/IGC.0b013e31819c5372.

107. Nomura H. et al. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial//JAMA oncology. - 2019. - Т. 5. - N. 6. - С. 833 - 840.

108. Fleming G. F. et al. Phase III randomized trial of doxorubicin+ cisplatin versus doxorubicin+ 24-h paclitaxel+filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study//Annals of Oncology. - 2004. - Т. 15. - N. 8. - С. 1173 - 1178.

109. Michener C. M. et al. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma//Journal of cancer research and clinical oncology. - 2005. - Т. 131. - N. 9. - С. 581 - 584.

110. Greven K. et al. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer//Gynecologic oncology. - 2006. - Т. 103. - N. 1. - С. 155 - 159.

111. Dimopoulos M.A. et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study//Gynecologic oncology. - 2000. - Т. 78. - N. 1. - С. 52 - 57.

112. Miller, D., Filiaci, V., Fleming, G., Mannel, R., Cohn, D., Matsumoto, T., ... Zaino, R. (2012). Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology, 125(3), 771. doi: 10.1016/j.ygyno.2012.03.034

113. Homesley H.D. et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study//Journal of Clinical Oncology. - 2007. - Т. 25. - N. 5. - С. 526 - 531.

114. Fader A.N. et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. - 2018

115. Sutton G. et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study//Gynecologic oncology. - 2005. - Т. 96. - N. 3. - С. 630 - 634.

116. Zhang Y. et al. Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis//World journal of surgical oncology. - 2015. - Т. 13. - N. 1. - С. 208.

117. Ethier, J.-L., Desautels, D.N., Amir, E., & MacKay, H. (2017). Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecologic Oncology, 147(1), 158 - 166. doi: 10.1016/j.ygyno.2017.07.002

118. Thigpen J.T. et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group//Journal of Clinical Oncology. - 1999. - Т. 17. - N. 6. - С. 1736 - 1736

119. Thigpen T. et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study//Journal of Clinical Oncology. - 2001. - Т. 19. - N. 2. - С. 364 - 367.

120. Barker L.C., Brand I. R., Crawford S. M. Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma//Current medical research and opinion. - 2009. - Т. 25. - N. 5. - С. 1105 - 1109.

121. Lindemann K. et al. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)//BMC cancer. - 2014. - Т. 14. - N. 1. - С. 68.

122. Reed, N.S., Mangioni, C., , H., Scarfone, G., Poveda, A., Pecorelli, S.,... Vermorken, J. B. (2008). Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). European Journal of Cancer, 44(6), 808 - 818.

123. Judson I. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial//The lancet oncology. - 2014. - Т. 15. - N. 4. - С. 415 - 423.

124. Hensley M.L. et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial//Journal of Clinical Oncology. - 2002. - Т. 20. - N. 12. - С. 2824 - 2831.

125. Ethier, J.-L., Desautels, D. N., Amir, E., & MacKay, H. (2017). Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecologic Oncology, (1), 158 - 166. doi: 10.1016/j.ygyno.2017.07.002

126. Pautier P. et al. A phase 2, randomized, open-label study of irosustat versus megestrol acetate in advanced endometrial cancer//International Journal of Gynecologic Cancer. - 2017. - Т. 27. - N. 2. - С. 258 - 266.

127. Dizon, D.S. (2010). Treatment options for advanced endometrial carcinoma. Gynecologic Oncology, 117(2), 373 - 381. doi: 10.1016/j.ygyno.2010.02.007

128. Escobar P.F. et al. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer//Journal of cancer research and clinical oncology. - 2003. - Т. 129. - N. 11. - С. 651 - 654.

129. Fracasso P.M. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study//Gynecologic oncology. - 2006. - Т. 103. - N. 2. - С. 523 - 526.

130. Markman M. et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study//Gynecologic oncology. - 2006. - Т. 101. - N. 3. - С. 436 - 440.

131. Homesley H.D. et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer//International journal of clinical oncology. - 2008. - Т. 13. - N. 1. - С. 62 - 65.

132. Lissoni A. et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer//Annals of Oncology. - 1996. - Т. 7. - N. 8. - С. 861 - 863.

133. Lincoln S. et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study//Gynecologic oncology. - 2003. - Т. 88. - N. 3. - С. 277 - 281.

134. Blay J.Y. et al. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study//British journal of cancer. - 2019. - Т. 120. - N. 11. - С. 1026.

135. Anderson S., Aghajanian C. Temozolomide in uterine leiomyosarcomas//Gynecologic oncology. - 2005. - Т. 98. - N. 1. - С. 99 - 103.

136. Blay J.Y. et al. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study//British journal of cancer. - 2019. - Т. 120. - N. 11. - С. 1026.

137. Jhingran A., Burke T. W., Eifel P. J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy//International Journal of Radiation Oncology* Biology* Physics. - 2003. - Т. 56. - N. 5. - С. 1366 - 1372.

138. Campagnutta E. et al. Surgical treatment of recurrent endometrial carcinoma//Cancer: Interdisciplinary International Journal of the American Cancer Society. - 2004. - Т. 100. - N. 1. - С. 89 - 96.

139. Vargo J.A. et al. Definitive salvage for vaginal recurrence of endometrial cancer: the impact of modern intensity-modulated-radiotherapy with image-based HDR brachytherapy and the interplay of the PORTEC 1 risk stratification//Radiotherapy and Oncology. - 2014. - Т. 113. - N. 1. - С. 126 - 131.

140. Havrilesky L.J. et al. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer//Gynecologic oncology. - 2005. - Т. 99. - N. 3. - С. 689 - 695.

141. Dowdy S.C. et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes//Gynecologic oncology. - 2006. - Т. 101. - N. 2. - С. 280 - 286.

142. Vale C.L. et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma//Cochrane Database of Systematic Reviews. - 2012. - N. 8.

143. Emons, et al. "Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities." Geburtshilfe und Frauenheilkunde vol. 78, 11 (2018): 1089 - 1109. doi: 10.1055/a-0715-2964

144. Sutton G.P. et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium//Cancer. - 1994. - Т. 73. - N. 5. - С. 1453 - 1455.

145. Temkin S.M., Fleming G. Current Treatment of Metastatic Endometrial Cancer/Cancer Control/January 2009, Vol. 16, No. 1. p. 38.

146. Look K.Y., Sandler A., Blessing J.A., Lucci 3rd J.A., Rose P.G. Gynaecologic Oncology Group (GOG) Study. Phase II trial of gemcitabine as secondline chemotherapy of uterine leiomyosarcoma: a Gynaecologic Oncology Group (GOG) Study//Gynaecol. Oncol. - 2004. - Vol. 92. - P. 644647

147. А.Ф. Урманчеева, Е.А. Ульрих. Принципы лечения сарком матки./Практическая онкология, Т. 9, N 3. - 2008, стр. 132 - 136

148. Morgan J. A., Cesne A. Le, Chawla S. M. et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (Lsarcomas) after failure of prior anthracylines (A) and ifosfamide (I) Journal of Clinical Oncology//ASCO Annual Meeting Proceedings (PostMeeting Edition). - 2007. - Vol. 25, N 18S (June 20 Supplement). - P. 10060.

149. Ульрих Е.А. Особенности лечения сарком матки/Практическая онкология, Т 14. N 2 - 2013, стр. 127 - 134

150. Стуков А.Н. и соавт. Фармакотерапия опухолей/Под ред. А.Н. Стукова, М.А. Бланка, Т.Ю. Семиглазовой, А.М. Беляева. СПб: Издательство АНО "Вопросы онкологии", 2017, 512 с.

151. Jiang, H., Gupta, R., & Somma, J. (2013). EZH2, a unique marker of malignancy in effusion cytology. Diagnostic Cytopathology, 42(2), 111 - 116. doi: 10.1002/dc.22999